Alacrita is Pleased to Support NICE/UKTI Scientific Advice Seminars

Alacrita is pleased to support a series of seminars in a variety of locations across the United States. The seminars will cover:

  • “Value” from the perspective of NICE
  • How value propositions link to the need for specific evidence
  • The types of evidence considered by NICE
  • The general principles of health technology assessment

The seminars are designed for developers of devices and diagnostics, but we would encourage investors and other interested parties to attend.

The seminar program is funded by UKTI to allow free attendance.

Monday, October 27, 2014

Washington D.C.
Tuesday, October 28, 2014

New York
Wednesday, October 29, 2014

Thursday, October 30, 2014

Read our WhitePaper: Why it is critical to undestand the needs of European Payers

There is increasing divergence between the evidence regulators need for approval, and that needed by payers for reimbursement. Whilst ignoring the needs of European payers before entering Phase 3 imperils the prospects of a drug’s success, a clear market access strategy informs development decisions and underpins global partnering discussions… read the WhitePaper »

Alacrita Provides Strategic Market Access Support

Our market access team are experienced in helping companies ensure a pivotal trial program generates the evidence required to demonstrate value. Failing to incorporate ‘value’ endpoints in clinical trials may jeopardize the value of the asset in international markets. Market access uncertainty can also be at the root of much skepticism surrounding the value of an asset in a transaction… Read case studies describing how we helped position US biotech companies for European reimbursement success »

Share on FacebookShare on Google+Tweet about this on TwitterShare on LinkedIn

Stay in touch